StockTipsArenaBeta

BUY Mankind Pharma Limited — Chandan Taparia, Motilal Oswal

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

byChandan Taparia, Motilal OswalHorizon: NA (inferred Swing (≤2wk))20 May 2026via NDTV Profit

Entry₹2,583.9Inferred
Target₹2,700
Total upside +4.49% (call closed)
Stop lossNot given
At expiry₹2,372.33 Jun 2026, 3:30 pm
Expired-8.19%
Follow Chandan Taparia for new calls(30% target hit, 259 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:49 pm IST
5 supporting2 neutral0 opposing
Supports the BUY call (5)

Mankind Pharma Limited, through its subsidiary, acquired the remaining 10% stake in Upakarma Ayurveda Private Limited, making Upakarma a wholly-owned subsidiary. This acquisition aims to improve opera

NSE · Acquisition·2 Jun · today

(opens in new tab)

Mankind Pharma Ltd has informed about a stake acquisition by one of its wholly-owned subsidiary companies.

BSE · Company Update·2 Jun · today

(opens in new tab)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·3 Jun · today

Mankind Pharma announced its Q4FY26 and FY26 financial results. Revenue increased by 11.8% YoY to INR 3,443 Cr in Q4FY26, with Adj. EBITDA margin at 27.1%. FY26 revenue grew 17.0% to INR 14,278 Cr.

NSE · Press Release·19 May · 2w ago

(opens in new tab)

Mankind Pharma reported Q4FY26 & FY26 financial results. Revenues increased 11.8% YoY to INR 3,443 Cr in Q4FY26 and 17.0% YoY to INR 14,278 Cr in FY26. Adj. EBITDA margin was 27.1% in Q4FY26.

BSE · Company Update·19 May · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Mankind Pharma to meet investors in Mumbai on June 1-2

NewsGoogle News·27 May · 6d ago

(opens in new tab)

Please find attached Audited Financail Results for the quarter and year ended March 31, 2026

BSE · Board Meeting·19 May · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Chandan Taparia, Motilal Oswal

Every call and its outcome